Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05600777 · ClinicalTrials.gov registry record · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
A Phase 3 study of Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
- 20
- Study locations
NCT05600777: Recruiting Phase 3 study of Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company.
NCT05600777 is a Phase 3 study of Cough and Refractory Chronic Cough that is actively recruiting participants, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 975 participants, above the 141-participant average among 12 other Cough trials with a reported enrollment target (591% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05600777, a Phase 3 study of Cough and Refractory Chronic Cough, is actively recruiting participants, sponsored by Bellus Health Inc. - a GSK company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Primary Outcome
Assessed using an ambulatory cough monitor
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BLU-5937
Study Locations (20)
Florida
- GSK Investigational Site - Daytona Beach
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Leesburg
- GSK Investigational Site - Santa Rosa Beach
- GSK Investigational Site - Sarasota
- GSK Investigational Site - Sweetwater
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Paramount
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Jose
Colorado
- GSK Investigational Site - Aurora
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Wheat Ridge
Alabama
- GSK Investigational Site - Foley
Arizona
- GSK Investigational Site - Phoenix
District of Columbia
- GSK Investigational Site - Washington D.C.
Georgia
- GSK Investigational Site - Cumming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2022-12-05 |
| Est. Completion | 2027-03-23 |
| Phase | Phase 3 |
What NCT05600777 shows while recruiting
NCT05600777 is an interventional study that assigns participants to a tested intervention. The registered 975 participants enrollment target is mid-sized for trials with a published cap, above the 141-participant average among 12 other Cough trials with a reported enrollment target (591% higher).
The record links to 2 conditions, with Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05600777 names 20 study sites across 7 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05600777 about?
NCT05600777 is a clinical study titled "A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough". This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
What is the current status of trial NCT05600777?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2022-12-05. Estimated completion is 2027-03-23.
What conditions does trial NCT05600777 study?
This clinical trial studies the following conditions: Cough, Refractory Chronic Cough.
What interventions are being tested in trial NCT05600777?
The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).
Who is sponsoring clinical trial NCT05600777?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05600777 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05600777's enrollment target sits among peer trials
975 1st of 12 higher than 12 of 12 other Cough trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cough trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
-
Work of Breathing Assessment in Triage Scale
ACTIVE NOT RECRUITING
-
Stimulation With Wire Leads to Restore Cough
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
- NCT07216482 · 975 participants · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI